利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.025 秒)

    Pharmaceutically enhanced low-energy radiosurgery
    2.
    发明授权
    Pharmaceutically enhanced low-energy radiosurgery 失效
    药物强化低能放射外科手术

    公开(公告)号：US6125295A

    公开(公告)日：2000-09-26

    申请号：US140981

    申请日：1998-08-27

    申请人： Webster C. Cash, Jr. ,  Michael D. Weil

    发明人： Webster C. Cash, Jr. ,  Michael D. Weil

    IPC分类号： A61K41/00 ,  A61N5/10 ,  A61B6/00

    CPC分类号： A61N5/10 ,  A61K41/0085 ,  A61N2005/1091 ,  A61N2005/1098

    摘要： Contrast agents developed specifically for x-ray diagnostics provide dose-enhanced radiotherapy and radiosurgery. The presence of heavy elements from these contrast agents, even small quantities, leads to a major dose increase in target tissue. When combined with in vivo calibration of the amount of contrast agent, the procedure is quick, accurate, and safe. The technique can also be used in combination with other techniques, such as focused x-rays, to achieve further enhancement of therapeutic ratio. Through optimization of the equipment it is possible to achieve very large ratios of dose in target to dose in healthy tissue up to 10:1.

    摘要翻译： 专为x射线诊断开发的造影剂可提供剂量增强的放射治疗和放射外科手术。 来自这些造影剂的重元素甚至少量的存在导致靶组织中主要的剂量增加。 结合造影剂量的体内校准时，手术快速，准确，安全。 该技术还可以与诸如聚焦X射线的其它技术结合使用，以进一步提高治疗比。 通过设备的优化，可以在健康组织中达到非常大的剂量比例，达到10：1。

    Targeted Nuclear Fusion Tumor Therapy
    3.
    发明申请
    Targeted Nuclear Fusion Tumor Therapy 审中-公开
    靶向核融合肿瘤治疗

    公开(公告)号：US20140100409A1

    公开(公告)日：2014-04-10

    申请号：US14031715

    申请日：2013-09-19

    申请人： Milford Burton Kime

    发明人： Milford Burton Kime

    IPC分类号： A61N5/10

    CPC分类号： A61N5/1001 ,  A61K41/0004 ,  A61K41/0085 ,  A61N5/1039 ,  A61N5/1077 ,  A61N2005/1087

    摘要： A method and apparatus for treating a tumor in a patient. In one embodiment, the method comprises the steps of: dosing the patient with a substituted tumor-specific agent and irradiating the tumor with energetic ions, the ions having sufficient energy to penetrate into the tumor and cause nuclear fusion reactions, but not to pass through the tumor. In one embodiment, the substituted tumor-specific agent incorporates deuterium. In this embodiment, the energetic ions are tritium nuclei. In this embodiment, the apparatus comprises a tritium ion source, an accelerator producing an ion beam, a scanning mechanism, and a plurality of neutron detectors positioned adjacent to the patient. The tritium ion beam is programmed to traverse the site of the tumor with tritium ions having energy sufficient to penetrate into the tumor and cause nuclear fusion reactions, but not pass through the tumor.

    摘要翻译： 一种治疗患者肿瘤的方法和装置。 在一个实施方案中，该方法包括以下步骤：向患者给予取代的肿瘤特异性试剂并用能量离子照射肿瘤，所述离子具有足够的能量以穿透入肿瘤并引起核聚变反应但不通过 肿瘤。 在一个实施方案中，取代的肿瘤特异性试剂掺入氘。 在这个实施例中，能量离子是氚核。 在该实施例中，该装置包括氚离子源，产生离子束的加速器，扫描机构和位于患者附近的多个中子探测器。 氚离子束被编程为用具有足够的能量的氚离子穿过肿瘤部位以渗透到肿瘤中并引起核聚变反应，但不通过肿瘤。

    Methods for detection and quantification of cell subsets within subpopulations of a mixed cell population
    5.
    发明授权
    Methods for detection and quantification of cell subsets within subpopulations of a mixed cell population 失效
    用于在混合细胞群体的亚群内检测和定量细胞亚群的方法

    公开(公告)号：US5385822A

    公开(公告)日：1995-01-31

    申请号：US619838

    申请日：1990-11-29

    申请人： Meryle J. Melnicoff ,  Bruce D. Jensen ,  Katharine A. Muirhead ,  Paul K. Horan ,  Martin D. Summers ,  William Wong

    发明人： Meryle J. Melnicoff ,  Bruce D. Jensen ,  Katharine A. Muirhead ,  Paul K. Horan ,  Martin D. Summers ,  William Wong

    IPC分类号： C07D209/12 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/18 ,  C07C229/16 ,  C07D209/08 ,  C07D219/08 ,  C07D263/62 ,  C07D307/94 ,  C07D493/10 ,  G01N33/53 ,  G01N33/553 ,  G01N33/569 ,  C12Q1/70

    CPC分类号： A61K41/0085 ,  A61K47/48215 ,  A61K49/0002 ,  A61K49/0032 ,  A61K49/06 ,  A61K49/18 ,  A61K49/1896 ,  C07C229/16 ,  C07D209/08 ,  C07D219/08 ,  C07D263/62 ,  G01N33/569 ,  G01N33/56972 ,  Y10S435/975

    摘要： The presence or quantity of a selected subset of cells, which is part of a subpopulation of a mixed cell population, is determined by a method in which a detectable reporter substance is uniformly incorporated into substantially all cells of the subpopulation containing the subset of interest. The subset of interest is then affinity-separated by incubating a test sample of the mixed cell population containing the labeled subpopulation with a specific binding substance which selectively binds to characteristic determinants of the cell subset of interest. Occurrence of the reporter substance in the separated fraction is then detected, and correlated to a predetermined standard to determine the presence or quantity of the subset of interest within the cell population. According to another aspect of the invention a method is provided for quantitating two or more selected subsets of cells within a subpopulation of a mixed cell population. After labeling, the entire subpopulation is affinity-separated from the mixed cell population, and occurrence of the reporter substance in the separated fraction is detected. Next, subsets of interest within the subpopulation are affinity-separated as described above, and the level of detected reporter substance in each subset is compared to the level detected in the entire subpopulation. According to further aspects of the invention test kits are provided for performing the above-described methods.

    摘要翻译： 作为混合细胞群的亚群的一部分的所选择的细胞亚群的存在或数量通过其中可检测的报告物物质被均匀地并入包含感兴趣亚群的亚群的基本上所有细胞的方法来确定。 然后通过将含有标记亚群的混合细胞群体的测试样品与选择性结合感兴趣的细胞亚群的特征决定簇的特异性结合物质孵育来将感兴趣的亚组亲和力分离。 然后检测分离部分中报道物质的发生，并与预定标准相关，以确定细胞群体内感兴趣亚群的存在或数量。 根据本发明的另一方面，提供了一种用于定量混合细胞群体的亚群内的两个或多个选定细胞亚群的方法。 标记后，将整个亚群与混合细胞群进行亲和分离，并检测分离部分中报道物质的发生。 接下来，亚群内感兴趣的亚群如上所述进行亲和力分离，并将每个子集中检测到的报道物质的水平与整个亚群中检测到的水平进行比较。 根据本发明的其它方面，提供了用于执行上述方法的测试试剂盒。

    Mossbauer cancer therapy
    6.
    发明授权
    Mossbauer cancer therapy 失效
    莫斯堡癌症治疗

    公开(公告)号：US4815448A

    公开(公告)日：1989-03-28

    申请号：US849046

    申请日：1986-04-07

    申请人： Randell L. Mills

    发明人： Randell L. Mills

    IPC分类号： A61K51/00 ,  A61K41/00 ,  A61K51/12 ,  A61N5/10 ,  A61N5/12

    CPC分类号： A61N5/10 ,  A61K41/0085 ,  A61K51/12 ,  A61K2121/00 ,  A61N2005/1098

    摘要： Frequency selective radiation therapy providing selective tissue damage or necrosis by irradiating a component element of the target tissue at the corresponding Mossbauer absorption frequency. The component radiation absorption at the Mossbauer absorption frequency is thus enhanced many times over the absorption of the surrounding tissue having a different Mossbauer absorption frequency. The energy thusly absorbed by the target tissue component is converted to and remitted as Auger electrons, which provide intranuclear radiation resulting in lethal double strand breaks in the DNA molecules of the target tissue. The therapy is administered in frequency and tissue selective modes of treatment, and may be combined with conventional chemotherapeutic agents to provide a further enhanced treatment modality. Moreover, the source frequency can be adjusted to enhance the killing effect. The therapy method and apparatus according to the present invention is useful in combination with naturally occurring or administered pharmaceutical stable isotope absorbers, having significantly reduced side effects by comparison to conventional chemotherapy or radiation therapy.

    摘要翻译： 频率选择性放射治疗通过以相应的莫斯鲍尔吸收频率照射靶组织的组分元件来提供选择性组织损伤或坏死。 因此，莫斯鲍尔吸收频率下的成分辐射吸收比具有不同莫斯鲍尔吸收频率的周围组织的吸收增强许多次。 由靶组织成分所吸收的能量被转换并作为俄歇电子排出，其提供核内辐射，导致目标组织的DNA分子中的致死双链断裂。 治疗以频率和组织选择性治疗模式施用，并且可以与常规化学治疗剂组合以提供进一步增强的治疗方式。 此外，可以调整源频率以增强杀伤效果。 根据本发明的治疗方法和装置可与天然存在或给药的药物稳定同位素吸收剂组合使用，与常规化学疗法或放射治疗相比具有显着降低的副作用。

    Mossbauer cancer therapy
    7.
    发明授权
    Mossbauer cancer therapy 失效
    莫斯堡癌症治疗

    公开(公告)号：US4815447A

    公开(公告)日：1989-03-28

    申请号：US713448

    申请日：1985-03-19

    申请人： Randell L. Mills

    发明人： Randell L. Mills

    IPC分类号： A61K41/00 ,  A61K51/12 ,  A61N5/10 ,  A61N5/12

    CPC分类号： A61K41/0085 ,  A61K51/12 ,  A61N5/10 ,  A61K2121/00 ,  A61N2005/1098

    摘要： Frequency selective radiation therapy providing selective tissue damage or necrosis by irradiating a component element of the target tissue at the corresponding Mossbauer absorption frequency. The component radiation absorption at the Mossbauer absorption frequency is thus enhanced many times over the absorption of the surrounding tissue having a different Mossbauer absorption frequency. The energy thusly absorbed by the target tissue component is converted to and remitted as Auger electrons, which provide intranuclear radiation resulting in lethal double strand breaks in the DNA molecules of the target tissue. The therapy is administered in frequency and tissue selective modes of treatment, and may be combined with conventional chemotherapeutic agents to provide a further enhanced treatment modality. Moreover, the source frequency can be adjusted to enhance the killing effect. The therapy method and apparatus according to the present invention is useful in combination with naturally occurring or administered pharmaceutical stable isotope absorbers, having significantly reduced side effects by comparison to convention chemotherapy or radiation therapy.

    摘要翻译： 频率选择性放射治疗通过以相应的莫斯鲍尔吸收频率照射靶组织的组分元件来提供选择性组织损伤或坏死。 因此，莫斯鲍尔吸收频率下的成分辐射吸收比具有不同莫斯鲍尔吸收频率的周围组织的吸收增强许多次。 由靶组织成分所吸收的能量被转换并作为俄歇电子排出，其提供核内辐射，导致目标组织的DNA分子中的致死双链断裂。 治疗以频率和组织选择性治疗模式施用，并且可以与常规化学治疗剂组合以提供进一步增强的治疗方式。 此外，可以调整源频率以增强杀伤效果。 根据本发明的治疗方法和装置可与天然存在或给药的药物稳定同位素吸收剂组合使用，与常规化疗或放射治疗相比具有显着降低的副作用。

    Modulating a biological activity of a target structure by energy generation in-situ within a medium
    9.
    发明授权
    Modulating a biological activity of a target structure by energy generation in-situ within a medium 有权

    公开(公告)号：US09993661B2

    公开(公告)日：2018-06-12

    申请号：US15649956

    申请日：2017-07-14

    申请人： IMMUNOLIGHT, LLC.

    发明人： Frederic A. Bourke, Jr. ,  Harold Walder

    IPC分类号： A61N5/06 ,  A61N5/10 ,  A61K41/00

    CPC分类号： A61N5/062 ,  A61K41/0085 ,  A61N5/0622 ,  A61N5/1077 ,  A61N2005/0661 ,  A61N2005/1091 ,  A61N2005/1098

    摘要： A system and method for light stimulation within a medium. Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

    RADIATION ENHANCED MACROMOLECULAR DELIVERY OF THERAPEUTIC AGENTS FOR CHEMOTHERAPY TECHNOLOGY
    10.
    发明申请
    RADIATION ENHANCED MACROMOLECULAR DELIVERY OF THERAPEUTIC AGENTS FOR CHEMOTHERAPY TECHNOLOGY 审中-公开
    用于化疗技术的治疗药物的辐射增强大分子递送

    公开(公告)号：US20120197060A1

    公开(公告)日：2012-08-02

    申请号：US13378731

    申请日：2010-06-17

    申请人： Abhijit Ray ,  Hamidreza Ghandehari

    发明人： Abhijit Ray ,  Hamidreza Ghandehari

    IPC分类号： A61M37/00 ,  A61P35/00 ,  C07F15/00 ,  C08F222/38 ,  C07H23/00

    CPC分类号： A61K41/00 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/704 ,  A61K33/24 ,  A61K41/0085 ,  A61K47/58 ,  A61K47/595 ,  A61K47/60 ,  A61K47/65 ,  A61K47/6905 ,  A61N5/10 ,  C07F15/0093 ,  C07H23/00

    摘要： Described herein are anti-cancer compounds composed of a macromolecule comprising (1) at least one anti-cancer agent directly or indirectly bonded to the macromolecule and (2) at least one high Z element directly or indirectly bonded to the macromolecule that is capable of producing Auger electrons upon exposure to X-ray energy. When the compounds are exposed to low energy X-ray (e.g., kilo electron volts KeV) Auger electrons are produced by the high Z elements present in the compound. Because lower energy is required when compared to typical radiotherapy, which uses therapeutic X-ray energy in the million electron volt range (MeV), the subject experiences lower collateral damage when compared to radiation therapy. Additionally, the presence of the anti-cancer agent provides a second mechanism for killing cancer cells. Methods for making and using the anti cancer compounds are also described herein.

    摘要翻译： 本文描述了由大分子组成的抗癌化合物，其包含（1）直接或间接结合到大分子上的至少一种抗癌剂，和（2）至少一个直接或间接结合到大分子上的高Z元素，其能够 在暴露于X射线能量时产生俄歇电子。 当化合物暴露于低能量X射线（例如，千电子伏特KeV）时，由化合物中存在的高Z元素产生俄歇电子。 因为与使用百万电子伏范围（MeV）中的治疗性X射线能量的典型放射治疗相比，需要较低的能量，与放射治疗相比，受试者经历较低的附带损伤。 此外，抗癌剂的存在提供了杀死癌细胞的第二种机制。 本文还描述了制备和使用抗癌化合物的方法。